Synta's Merger With Madrigal Creates New Entrant In NASH Race
This article was originally published in The Pink Sheet Daily
Executive Summary
Moving past its late-stage clinical failure with ganetespib, Synta will combine with Madrigal to develop a Phase II-ready compound for NASH and hypercholesterolemia.